Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RZLT 
Rezolute Inc (RZLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: RZLT (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $14
1 Year Target Price $14
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 221.48% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 892.84M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 10 | Beta 0.05 | 52 Weeks Range 2.21 - 10.04 | Updated Date 10/23/2025 |
52 Weeks Range 2.21 - 10.04 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.98 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.4% | Return on Equity (TTM) -52.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 668313471 | Price to Sales(TTM) - |
Enterprise Value 668313471 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.01 | Shares Outstanding 90828052 | Shares Floating 76929942 |
Shares Outstanding 90828052 | Shares Floating 76929942 | ||
Percent Insiders 9.96 | Percent Institutions 92.19 |
Upturn AI SWOT
Rezolute Inc
Company Overview
History and Background
Rezolute, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies for metabolic diseases. Founded in 2010, it initially focused on developing treatments for diabetes and related complications. The company is headquartered in Redwood City, California.
Core Business Areas
- Hypoglycemia Programs: Rezolute is developing therapies focused on congenital hyperinsulinism (CHI) and other causes of severe hypoglycemia. These programs aim to address unmet needs in patients experiencing dangerously low blood sugar levels.
Leadership and Structure
The leadership team includes individuals with experience in pharmaceutical development and commercialization. The company operates with a functional structure, focusing on research and development, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- RZ358 (onisemtide): RZ358 is a monoclonal antibody being developed for the treatment of congenital hyperinsulinism (CHI). There are no market share numbers available as of October 26, 2024 because the drug is not approved by the FDA. The competitors are surgical removal of the pancreas.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long regulatory approval timelines, and intense competition. The metabolic disease therapeutics market is driven by the increasing prevalence of conditions such as diabetes and hypoglycemia.
Positioning
Rezolute is positioned as a specialty pharmaceutical company focused on addressing rare and underserved metabolic disease markets. Its competitive advantage lies in its targeted therapeutic approach and potential to address significant unmet medical needs.
Total Addressable Market (TAM)
The TAM for CHI and severe hypoglycemia therapies is substantial, given the lack of effective treatments and the potential for significant clinical benefit. Rezolute is positioned to capture a meaningful share of this market with successful development and commercialization of its lead candidate, RZ358.
Upturn SWOT Analysis
Strengths
- Targeted therapeutic approach
- Focus on underserved market segments
- Experienced leadership team
- Positive preclinical and clinical data for lead candidate
Weaknesses
- Limited financial resources
- Dependence on single lead candidate
- High regulatory risk
- Potential for competition from larger pharmaceutical companies
Opportunities
- Expansion into new metabolic disease indications
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Fast Track or Breakthrough Therapy designation from regulatory agencies
Threats
- Failure to obtain regulatory approval
- Competition from alternative therapies
- Adverse clinical trial results
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- SURGICAL REMOVAL OF PANCREAS
- Diazoxide
Competitive Landscape
Rezolute's competitive advantage lies in its targeted therapeutic approach compared to current off label treatments or surgical removal of the pancreas. Its disadvantage is its lack of an approved therapy and dependence on clinical trial success.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal as the company is pre-revenue and focused on drug development.
Future Projections: Future growth is highly dependent on the successful development and commercialization of RZ358 and other pipeline candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing RZ358 through clinical trials and seeking partnerships to support development.
Summary
Rezolute Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. Its lead candidate, RZ358, targets congenital hyperinsulinism (CHI). The company's success depends on positive clinical trial results and regulatory approval. Rezolute's lack of revenue and reliance on R&D funding pose significant risks. Potential for growth exists if RZ358 proves effective and gains market acceptance. The success of the company depends highly on RZ358 getting approved.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rezolute Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2014-05-01 | Founder, CEO, Principal Financial Officer & Acting Chairman of the Board Mr. Nevan Charles Elam J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 71 | Website https://www.rezolutebio.com |
Full time employees 71 | Website https://www.rezolutebio.com | ||
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.